EIS and VCT Qualifying Status and Issue of Equity

RNS Number : 5354Q

Immupharma PLC

01 March 2016

 

                                                                                                                                                                      1 MARCH 2016

ImmuPharma PLC

Confirmation of EIS and VCT Qualifying Status and Issue of Equity

£8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received advance assurance from HM Revenue and Customs that it is a qualifying holding for the purposes of the Venture Capital Trust rules ("VCT Advance Assurance") and a qualifying company for the purposes of the Enterprise Investment Scheme ("EIS Advance Assurance", together the "Assurances").

Following receipt of the Assurances, the Company is pleased to announce the issue and allotment of the 2,856,539 new ordinary shares of 10 pence each (the "New Ordinary Shares") in respect of the EIS Shares and VCT Shares within the Placing and Subscription as described in the announcements on 5 February 2016 and 24 February 2016. This brings the total proceeds raised by the Company in connection with the Placing and Subscription to £8.4 million.

Application will be made to the London Stock Exchange plc for the admission of the 2,856,539 New Ordinary Shares to trading on AIM ("Admission"). Admission is expected to take place at 8 a.m. on 4 March 2016 (or such later date as Panmure Gordon and the Company may agree, being not later than 8 a.m. on 24 March 2016) at which time the Placing and Subscription will become unconditional. Dealings in the New Ordinary Shares on AIM will commence at the same time. The New Ordinary Shares will be issued credited as fully paid and will be identical to, and rank pari passu in all respects with, the existing ordinary share capital in the Company, including the right to all dividends and other distributions declared, made or paid in respect of the existing ordinary share capital following the date of Admission.

Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 121,781,219 ordinary shares of 10 pence each (the "Ordinary Shares") in issue. No Ordinary Shares are held in treasury. Shareholders may use the above figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under section 5 of the FCA's Disclosure and Transparency Rules.

Ends

For further information please see the Company's website, www.immupharma.org, or contact:

ImmuPharma plc Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations	+ 44 (0) 20 7152 4080 + 44 (0) 7721 413496 [e-mail]
Panmure Gordon (Financial Adviser, Nominated Adviser & Broker) Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking	[phone]

Notes on Assurances

Shareholders should be mindful that EIS Advance Assurance and VCT Advance Assurance qualification rules are subject to change and no guarantees or assurance can be given in this regard.

 

END

 

 

LISSESFWUFMSELE